CAR-T PLATFORM

Personalized gene cell therapy for the treatment of cancer

CAR-T therapy is a type of immunotherapy where patient’s own immune cells are genetically engineered to specifically target cancer cells.

CAR-T therapy is a type of cell therapy where genetically modified immune cells
from the patient selectively attack cancer cells. `Kymriah`, was approved by the U.S.
FDA in 2017 and was the first CAR-T treatment available for patients. From Phase II
clinical trials, it boasted nearly 90% complete remission rate and has been called
a miracle anticancer drug.

zCAR-T allows for continuous modulation of CAR T-cell activity within patients

AbClon’s proprietary zCAR-T treatment is the next generation of CAR-T treatment whose modularity
can allows its to be used against various cancer targets as well modulating the activity of CAR-T cells within the patient.

Immune cells genetically engineered with zCAR-T are regulated via a switch molecule which
modulates not only the activity of the T-cells but also the cancer target. This modularity
allows for streamlining production of the treatment as well as minimizing any potential
side effects.

Advantages of zCAR-T platform

ON/OFF function
Controllable level of
immune response
Expansion of
cancer targets

Expansion of treatment possibilities to
solid cancer in addition to blood cancer
zCAR-T platform’s modular nature means that providing new
targeting instructions for zCAR-T cells is as simple as
swapping out the switch.

Pipeline derived from CAR-T platform

AT101
CAR-T treatment for CD19-positive hematologic cancer cells, developed with in-house NEST platform.

AT501
zCAR-T treatment for ovarian cancer mediated with Affibody switch molecules.

Designed by CHAIRONE

AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
T. +82-2109-1294
F. +82-2109-1296
E. abclon@abclon.com

CAR-T PLATFORM

Personalized gene cell therapy for the treatment of cancer

zCAR-T allows for continuous modulation of CAR T-cell activity within patients

Advantages of zCAR-T platform

Expansion of treatment possibilities to solid cancer in addition to blood cancer

Pipeline derived from CAR-T platform

Expansion of treatment possibilities to
solid cancer in addition to blood cancer